Table 5.
Multivariate Cox model for PFS/OS for (A) entire cohort and (B) PET-negative CR1 patients, where maintenance rituximab was modeled as a time-dependent covariate and all other variables time-independent covariates. MIPI was always included in each final model. The other variables in each final model were chosen based on a model-selection procedure where all baseline characteristics were initially considered and only those who reached p<0.2 in the selection process were kept in the final model.
| A. Entire Cohort a | PFS | OS | ||
|---|---|---|---|---|
|
| ||||
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Gender: Female vs. Male (Ref) | 0.56(0.32,0.98) | 0.044 | 0.63(0.31,1.27) | 0.19 |
| Blastoid variant: No vs. Yes (Ref) | 0.35(0.16,0.74) | 0.006 | 0.21(0.09,0.49) | <0.001 |
| Regimens pre-ASCT: 2–3 vs. 1 (Ref) | 1.49(0.95,2.32) | 0.083 | 1.82(1.07,3.09) | 0.026 |
| MIPI | ||||
| Intermediate/high vs. low risk (Ref) | 1.25(0.74,2.10) | 0.40 | 1.37(0.77,2.44) | 0.28 |
| Unknown vs. low risk (Ref) | 1.20(0.71,2.05) | 0.49 | 0.86(0.46,1.60) | 0.63 |
| ASCT year: 2007 and later vs. Before 2007 (Ref) | 0.55(0.34,0.89) | 0.014 | 0.44(0.24,0.81) | 0.008 |
| Disease status: PR1/CR2/PR2/PR3 vs. CR1 (Ref) | 1.48(0.93,2.37) | 0.10 | 1.43(0.84,2.45) | 0.19 |
| ASCT Conditioning: Radiation-based vs. Chemotherapy-only (Ref) | 0.69(0.45,1.06) | 0.087 | 0.50(0.31,0.83) | 0.007 |
| Maintenance rituximab: Yes vs. No (Ref) | 0.25(0.14,0.44) | <.001 | 0.17(0.07,0.38) | <.001 |
| B. PET negative CR1a,b | PFS | OSc | ||
|---|---|---|---|---|
|
| ||||
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
| Age | - | - | 1.10(1.01,1.21) | 0.033 |
| Gender: Female vs. Male (Ref) | 0.53(0.23,1.22) | 0.14 | 0.20(0.04,1.05) | 0.057 |
| Blastoid variant: No vs. Yes (Ref) | 0.20(0.06,0.62) | 0.006 | - | - |
| B Symptoms: No vs. Yes (Ref) | - | - | 0.36(0.10,1.32) | 0.12 |
| Regimens pre-ASCT: 2–3 vs. 1 (Ref) | 2.27(0.95,5.43) | 0.067 | - | - |
| MIPI | ||||
| Intermediate/high vs. low risk (Ref) | 2.20(0.93,5.19) | 0.072 | 1.09(0.28,4.18) | 0.91 |
| Unknown vs. low risk (Ref) | 2.40(1.02,5.68) | 0.046 | 0.36(0.09,1.43) | 0.15 |
| Maintenance rituximab: Yes vs. No (Ref) | 0.20(0.09,0.43) | <.0001 | 0.17(0.05,0.59) | 0.005 |
Abbreviations: CR, complete remission; ASCT, high-dose therapy; MIPI, mantle cell lymphoma International prognostic index; PR, partial remission.
Diagnosis year was not included in the multivariate analysis due to its high correlation with ASCT year.
Variables excluded: disease status due to all patients being CR1; pre-ASCT rituximab due to only 1 patient being “No”.
Blastoid variant was excluded due to small number which led to extreme/unstable estimate if included in the model.